SCHEMBL2236721

SCHEMBL2236721

CC(C)c1ccc2c(c1)CCc1c(C[C@H](CCCNC(=O)OC(C)(C)C)C(=O)O)ncn1-2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GAA P10253 1/20 0.43
ACE P12821 1/20 0.35
UTS2R Q9UKP6 1/20 0.34
DRD2 P14416 4/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
NPSR1 Q6W5P4 3/20 0.33
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
STK17B O94768 1/20 0.32
STK17A Q9UEE5 1/20 0.32
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235169 0.90 MEN1 (0.44) MEN1KMT2AGAAACECYP11B1
SCHEMBL2237252 0.90 MEN1 (0.44) MEN1KMT2AGAAACECYP11B1
SCHEMBL2234527 0.90 MEN1 (0.38) MEN1KMT2AGAAACEUTS2R
SCHEMBL2234628 0.89 MEN1 (0.43) MEN1KMT2AGAAACEDRD2
SCHEMBL2237078 0.89 MEN1 (0.43) MEN1KMT2AGAAACEDRD2
SCHEMBL2235325 0.89 MEN1 (0.43) MEN1KMT2AGAAACECYP11B1
SCHEMBL2356132 0.88 MEN1 (0.42) MEN1KMT2AGAAACEDRD2
SCHEMBL2235434 0.88 MEN1 (0.42) MEN1KMT2AGAAACECYP11B1
SCHEMBL2234466 0.88 MEN1 (0.47) MEN1KMT2AGAAACEDRD2
SCHEMBL2236787 0.88 MEN1 (0.47) MEN1KMT2AGAAACEDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 MEN1 4119/4885KMT2A 3664/4885GAA 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.